DV
Dividend Vision

XGN — Exagen Inc

Exagen Inc (XGN)

Total return is -61.1% over the past 6.9 years, 246.7 points behind SPY at 185.6%. Its deepest 1-year drawdown was 77.8%.

Exagen Inc. designs, develops, and commercializes diagnostic testing products under the AVISE brand for the assessment and management of rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. The company does not currently distribute to shareholders. Exagen appeals to investors seeking exposure to the diagnostics and healthcare testing sector rather than those focused on dividend income.

XGN key facts

Asset type
Stock
Asset class
Equity
Inception date
09/19/2019
Last close
$6.66
Market cap
$113,068,048
Average volume
154200.0
Beta
2.022
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.96